All In Biotech

NDA 009170 · Valeant

Mysoline

Primidone · Oral · Anti-epileptic Agent

NovelPriority review

Last checked: Nov 19, 2026Latest source record: Jun 10, 2020 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations

First approved

1954

Mar 8, 1954

Approved uses

1

Original approval plus efficacy supplements

Registered trials

6

0 Phase 3, 0 recruiting

FAERS reports

10,264

6,711 serious, 884 with death reported

AI brief across all sources

Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.

What it is approved for

From the label in effect Sep 10, 2026.

INDICATIONS AND USAGE MYSOLINE, used alone or concomitantly with other anticonvulsants, is indicated in the control of grand mal, psychomotor, and focal epileptic seizures. It may control grand mal seizures refractory to other anticonvulsant therapy.

Mechanism: ACTIONS MYSOLINE raises electro- or chemoshock seizure thresholds or alters seizure patterns in experimental animals. The mechanism(s) of primidone’s antiepileptic action is not known. Primidone per se has anticonvulsant activity as do its two metabolites, phenobarbital and phenylethylmalonamide (PEMA). In addition to its anticonvulsant activity, PEMA potentiates the anticonvulsant activity of phenobarbital in experimental animals.

Therapeutic areas: Neurology

Approval history

Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.

  • Mar 8, 1954 Original approval · Type 1 - New Molecular Entity · priority review
2 products under this application
  • MYSOLINE · PRIMIDONE 50MG · TABLET, ORAL · Prescription · TE AB
  • MYSOLINE · PRIMIDONE 250MG · TABLET, ORAL · Prescription · TE AB

Clinical trials

Interventional ClinicalTrials.gov studies with "Primidone" as an intervention, any sponsor and status, largest first.

All 6 trials

Most reported adverse reactions

FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.

Signals
  • drug ineffective845
  • fall673
  • fatigue650
  • tremor591
  • off label use509
  • dizziness508
  • diarrhoea506
  • nausea479
  • drug interaction410
  • headache407
  • somnolence392
  • dyspnoea368

FAERS reports by year

By the date FDA received the report.

View as table
YearReports
2004173
2005195
2006175
2007157
2008184
2009195
2010277
2011300
2012345
2013352
2014391
2015676
2016743
2017666
2018673
2019684
2020692
2021636
2022562
2023591
2024570
2025580
2026446

Recalls

0 FDA enforcement reports for this application.

No recalls on record for this application.

Shortages

FDA's drug shortage list.

Not on FDA's shortage list.

Medicare spending

CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.

Compare

Part D: Mysoline (Primidone)

2024 spending

$12.9M

Beneficiaries

311

2,051 claims

Per beneficiary

$41,489

$53.05 per unit

View as table
YearSpending
2020$14,901,520
2021$14,588,744
2022$13,512,438
2023$13,882,536
2024$12,903,028

Published evidence

PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.

All 88 on PubMed

Sponsor: Valeant

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.